Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2423
Abstract: Our aim was to investigate the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane alone followed by tailored treatment, either continued exemestane monotherapy or exemestane plus docetaxel–cyclophosphamide (TC) combination therapy, in postmenopausal patients… read more here.
Keywords: exemestane; response; treatment; group ... See more keywords
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2311
Abstract: Aromatase inhibitors (AIs) are the treatment of choice for hormone receptor–positive early breast cancer in postmenopausal women. None of the third‐generation AIs are superior to the others in terms of efficacy. We attempted to identify… read more here.
Keywords: efficacy anastrozole; breast cancer; exemestane; anastrozole exemestane ... See more keywords
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
Sign Up to like & getrecommendations! Published in 2017 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-017-4199-3
Abstract: Purpose Combining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors (Ki67 > 15%).MethodsThis randomized, multicenter, international, phase II… read more here.
Keywords: exemestane; ridaforolimus; positive breast; breast cancer ... See more keywords
Magnetic mesoporous silica nanoparticles as a theranostic approach for breast cancer: Loading and release of the poorly soluble drug exemestane.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of pharmaceutics"
DOI: 10.1016/j.ijpharm.2022.121711
Abstract: Exemestane has a limited aqueous solubility that leads to a very high variability in absorption when administrated orally. It is crucial to develop strategies to increase the solubility and bioavailability of this drug. To overcome… read more here.
Keywords: mesoporous silica; silica nanoparticles; breast cancer; release ... See more keywords
Potential repositioning of exemestane as a neuroprotective agent for Parkinson’s disease
Sign Up to like & getrecommendations! Published in 2017 at "Free Radical Research"
DOI: 10.1080/10715762.2017.1353688
Abstract: Abstract Parkinson’s disease (PD) is a neurodegenerative disorder characterised by selective degeneration of the nigral dopaminergic neurons, and neuroinflammation and oxidative stress are believed to be involved in its pathogenesis. In the present study, we… read more here.
Keywords: exemestane; repositioning exemestane; potential repositioning; disease ... See more keywords
A case of exemestane induced pseudocellulitis
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.13428
Abstract: Exemestane is an aromatase inhibitor increasingly incorporated into the treatment of hormone sensitive breast cancer. Pseudocellulitis describes an uncomplicated inflammation of the dermis and hypodermis from a noninfectious etiology. It presents with erythema, swelling, warmth… read more here.
Keywords: case exemestane; exemestane; pseudocellulitis; exemestane induced ... See more keywords
Abstract 4908: Exemestane worsens everolimus-associated stomatitis in cancer patients
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4908
Abstract: Everolimus is an antitumor drug usually indicated for the treatment of breast, kidney and neuroendocrine malignancies that inhibits the activation of the mammalian Target of Rapamycin (mTOR). Despite the efficacy and success of the treatment,… read more here.
Keywords: exemestane; everolimus associated; cancer; cancer patients ... See more keywords
A simple UPLC-MS/MS assay with a core-shell column for the determination of exemestane in human plasma for clinical application
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Mass Spectrometry"
DOI: 10.1177/14690667221126276
Abstract: Exemestane is one of the aromatase inhibitors and has been used to treat breast cancer by lowering estrogen levels. Accurate quantification of exemestane is important to set an optimal dose, and thus a simple assay… read more here.
Keywords: exemestane; human plasma; core shell; shell column ... See more keywords
Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy.
Sign Up to like & getrecommendations! Published in 2017 at "Nanomedicine"
DOI: 10.2217/nnm-2017-0247
Abstract: AIM Oral administration of exemestane (EXM) and resveratrol (RES) for breast cancer therapy has been limited by their poor solubility and low permeability. METHODS In this study, these issues were tackled using zein nanocapsules (ZNCs)… read more here.
Keywords: shell; exemestane; breast cancer; cancer ... See more keywords